Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wuhan Back In Spotlight As Delta Variant Highlights Booster Shots Urgency

Delta Variant Poses New Challenges To China

Executive Summary

Amid surging infections in several cities including Wuhan, China is urging vaccination among unvaccinated people, but a booster shot may be needed soon to address a low efficacy among Chinese vaccines, some say.

You may also be interested in...



Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge

Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China

China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel